SCHEDULE: Maverick Capital Discloses 2.3% Stake in Rocket Pharma

Maverick Capital, Ltd. and its affiliates reported a 2.3% beneficial ownership stake in Rocket Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III collectively reported beneficial ownership of 2,513,110 shares of Rocket Pharmaceuticals, Inc. common stock.
• This ownership represents 2.3% of the outstanding shares of Rocket Pharmaceuticals, Inc.
• The percentage is based on 108,222,228 outstanding shares as of October 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 6, 2025.
• Maverick Capital, Ltd. acts as an investment adviser for its clients, including Maverick HP, L.P. (holding 1,917,698 shares) and separately managed accounts (holding 595,412 shares).
• Maverick Capital Management, LLC is the General Partner of Maverick Capital, Ltd., and Lee S. Ainslie III is the manager of Maverick Capital Management, LLC.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it confirms continued institutional interest from Maverick Capital in Rocket Pharmaceuticals, Inc. The 2.3% stake is a notable position, suggesting confidence in the company's value proposition, though it does not imply a controlling or activist intent.

Positives

• The disclosure of a 2.3% stake by Maverick Capital, a notable institutional investor, indicates continued institutional interest in Rocket Pharmaceuticals, Inc.

Future Outlook

NA

Management Comments

• Lee S. Ainslie III, Manager of Maverick Capital Management, LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures, such as this Schedule 13G, provide transparency into significant investor positions. For a biotechnology company like Rocket Pharmaceuticals, a 2.3% stake from an established investment firm like Maverick Capital can signal confidence in the company's long-term prospects, particularly its gene therapy pipeline, within a highly competitive and capital-intensive industry.

Comparison to Industry Standards

• A 2.3% stake is a significant, but not controlling, institutional position. For comparison, other major biotech firms often see institutional ownership percentages ranging from 50% to over 90%, with individual funds holding stakes from under 1% to over 10%. For instance, Vanguard Group and BlackRock often hold passive stakes of 5-10% or more in many large-cap biotechs like Amgen or Gilead Sciences. Maverick Capital's stake in Rocket Pharmaceuticals is a notable active investment, indicating a specific conviction rather than broad market indexing.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially signaling validation of the company's investment thesis by a sophisticated investor.
• Management: Awareness of a notable institutional holder can influence strategic decisions and communication with the investment community.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a beneficial ownership stake by Maverick Capital. While the institutional interest is a positive indicator, the filing itself does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. It confirms an existing institutional position, suggesting a 'hold' stance for investors awaiting further fundamental updates on Rocket Pharmaceuticals' performance and pipeline.

Keywords

Rocket Pharmaceuticals, Maverick Capital, Institutional Ownership, Beneficial Ownership, Gene Therapy, Biotechnology, SEC Filing, Schedule 13G